Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Astellas Pharma takes third spot in retail investor "buy" rankings on Minkabu
Notice Regarding Impairment Loss and Extraordinary Losses in Non-consolidated Financial Results(J-GAAP)
Notice of Nominees for Directors
Presentation Material for Information Meeting (FY2025)
Supplementary Documents (FY2025)
Financial Results (FY2025)
Astellas Pharma, 3% Increase in Net Income, Update Record High for Second Consecutive Term, Dividend Raised by 2 Yen
FRONTEO surges on AI drug discovery partnership with Astellas Pharma
Presentation Material for Astellas R&D Day (FY2025)
Astellas and Hovon Confirm Phase 3 Study Did not Meet its Primary Endpoint of Overall Survival in Patients with Newly Diagnosed FLT3m+ AML
Presentation Material for Sustainability Meeting (FY2025)
Astellas Reaches Settlement Agreements with Lupin and Zydus in Myrbetriq Patent Litigation
Supplementary Documents (Q3 YTD/FY2025)
Astellas Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 39%, Highest in Seven Terms
Financial Results (Q3 YTD/FY2025)
Presentation Material for information Meeting (Q3 YTD/FY2025)
Notice Regarding Revision of Financial Forecasts for FY2025
PADCEV Plus Keytruda Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Astellas Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 38%
Financial Results (Q2 YTD/FY2025)